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African swine fever virus (ASFV) causes an acute haemorrhagic disease of domestic pigs against which
there is no effective vaccine. The attenuated ASFV strain OUR T88/3 has been shown previously to protect
vaccinated pigs against challenge with some virulent strains including OUR T88/1. Two genes, DP71L and
DP96R were deleted from the OUR T88/3 genome to create recombinant virus OUR T88/3ΔDP2. Deletion
of these genes from virulent viruses has previously been shown to reduce ASFV virulence in domestic
pigs. Groups of 6 pigs were immunised with deletion virus OUR T88/3ΔDP2 or parental virus OUR T88/3
and challenged with virulent OUR T88/1 virus. Four pigs (66%) were protected by inoculation with the
deletion virus OUR T88/3ΔDP2 compared to 100% protection with the parental virus OUR T88/3. Thus the
deletion of the two genes DP71L and DP96R from OUR T88/3 strain reduced its ability to protect pigs
against challenge with virulent virus.
Crown Copyright & 2013 Published by Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
African swine fever is a devastating haemorrhagic disease of
domestic pigs caused by a double-stranded DNA virus, African
swine fever virus (ASFV). ASFV is the only member of the
Asfarviridae family and replicates predominantly in the cytoplasm
of cells (Dixon et al., 2000). The virus replicates in macrophages
and those cells with markers characteristic of intermediate and
late stages of differentiation which are susceptible to infection
(McCullough et al., 1999).
Virulent strains of ASFV can kill domestic pigs within about
5–14 days of infection with a mortality rate approaching 100%.
Domestic pigs infected with less virulent isolates can survive
infection and recovered pigs can gain immunity to subsequent
challenge with non-virulent and related virulent viruses (Detray,
1957; Boinas et al., 2004 and King et al., 2011).
ASFV can infect and replicate in warthogs (Phacochoerus sp.),
bushpigs (Potamocherus sp.) and soft ticks of the Ornithodoros
species, but in these species few if any clinical signs are observedevier Inc.
.C. Abrams).
Open access under CC BY-Nand long term persistent infections can be established (Wilkinson,
1984). The disease is currently endemic in many sub-Saharan
countries and in Europe in Sardinia. Following its introduction to
Georgia in the Trans Caucasus region in 2007, ASFV has spread
extensively through neighbouring countries including the Russian
Federation and in 2012 the ﬁrst outbreak was reported in Ukraine
(Malogolovkin et al., 2012). Virus has been detected in wild boar in
a number of different locations in both southern and western
Russia. If ASFV becomes established in wild boar, the difﬁculty of
disease eradication will be increased (Blome et al., 2012).
Although no vaccine is available for ASFV, it has been known
for many years that pigs which recover from infection with less
virulent isolates can be protected from challenge with related
virulent viruses (Detray, 1957; Malmquist, 1963; Mebus and
Dardiri, 1980). In addition pigs immunised with naturally attenu-
ated ASFV or viruses attenuated by passage in tissue culture can
also be protected from challenge with virulent viruses (Manso-
Ribeiro et al., 1963; Leitao et al., 2001; Boinas et al., 2004 and King
et al., 2011). For example Manso-Ribeiro et al., 1963 showed that
virus attenuated by passage in porcine bone marrow culture when
inoculated into pigs protected them against challenge with virulent
virus. However, a substantial proportion of the vaccinated pigs
developed unacceptable post-vaccination reactions including pneu-
monia, locomotor disturbances, skin ulcer, abortion and death.
Mechanisms of protection induced by attenuated viruses have
been investigated. A role for antibodies in protection is suggested byC-ND license.
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Fig. 1. Schematic diagram showing generation of recombinant ASF virus OUR T88/
3ΔDP2 with the deletion of the DP71L and DP96R genes. Recombinant virus OUR
T88/3ΔDP2 was created by homologous recombination between the MGF360 18R
and MGF360 19R genes on the wild type OUR T88/3 genome and transfer vector
plasmid pΔDP2loxPGUS resulting in the deletion of the DP71L and DP96R genes
and the insertion of vp72GUS gene.
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pigs to naïve pigs could confer protection against virulent challenge
(Wardley et al., 1985; Onisk et al., 1994). Evidence suggests that
neutralising antibodies are not fully effective but other protective
roles for antibodies are possible (Zsak et al., 1993; Ruiz-Gonzalvo
et al., 1983; Gómez-Puertas and Escribano, 1997). CD8+ T cells appear
to have an essential role in protection induced by the OUR T88/3
isolate since depletion of this cell subset abrogated protection against
challenge with virulent OUR T88/1 isolate (Oura et al., 2005). Further
evidence for a role of IFNγ producing lymphocytes in protection
comes from experiments showing that cross-protection induced by
the OUR T88/3 isolate, against challenge with virulent isolates from
different genotypes, was correlated with the ability of those isolates
to speciﬁcally stimulate IFNγ producing lymphocytes from the
immunised pigs (King et al., 2011).
Inoculation of recombinant viruses generated by the deletion of
genes from virulent viruses, including 9GL or DP71L, has been shown
to reduce virus virulence and protect pigs against challenge with the
parental virulent virus (Zsak et al., 1996, 1998; Lewis et al., 2000).
Deletion of other genes has been shown to reduce virus virulence but
the effect of their deletion on induction of protective immunity has
not yet been studied (Tulman et al., 2009).
The DP71L gene is present in genomes of ASFV isolates encoding
either a long form, 184 amino acids, or short form, 70–72 amino acids
(Sussman et al., 1992; Vydelingum et al., 1993; Goatley et al., 1999). A
conserved carboxy-terminal domain of 56 amino acids is present in
both forms of DP71L and in the Herpes simplex virus neurovirulence
factor ICP34.5 and host genes GADD34 and MyD116 (Goatley et al.,
1999). These genes share the function of dephosphorylating eukar-
yotic translation initiation factor 2 alpha (eIF-2α) by recruiting protein
phosphatase 1 catalytic subunit (PP1c) to dephosphorylate eIF-2α
(Rivera et al., 2007; Zhang et al., 2010). However in cells infected with
DP71L gene deletion mutants in the ASFV E70 and Malawi LIL20/1
strains, phosphorylation of eIF-2α was still inhibited, suggesting that
the virus has other mechanism to inhibit this pathway. In eukaryotic
cells, control of the availability of active non-phosphorylated eIF-2α by
reversible phosphorylation is the key and rate-limiting step regulating
global protein synthesis (Wek et al., 2006). eIF-2α can be phosphory-
lated by a number of different kinases, including the double-stranded
RNA activated PKR and stress activated PERK kinases, and viruses have
evolved speciﬁc mechanisms to inhibit these pathways and hence
reduce the inhibition of global protein synthesis (Mulvey et al., 2007;
Poppers et al., 2000 and Sharp et al., 1998).
Inoculation of pigs with a deletion mutant of the virulent E70
strain of ASF lacking the short form of DP71L resulted in reduced
virus virulence and all convalescent animals survived challenge with
the virulent parental E70 strain (Zsak et al., 1996). Conversely, Afonso
et al., 1998 showed that the deletion of the long form of DP71L gene
from the virulent strains Malawi 20/1 and Pr4 did not reduce virus
virulence and that inoculation with the recombinant deletion viruses
caused 100% mortality. Deletion of the DP71L gene from all three
strains E70, Malawi LIL20/1 and Pr4 did not alter the ability of the
recombinant virus to replicate in macrophages in vitro. The attenu-
ated E70ΔDP71L virus was restored to virulence by insertion of a
20 kb fragment of ASFV DNA including three members of multigene
family (MGF) 360 and three members of MGF 530 into its genome.
These results suggest that other genes may compensate for the loss
of DP71L in some isolates (Neilan et al., 2002).
The DP96R gene is located at the right hand of the genome
immediately downstream of the DP71L gene and is highly conserved
sharing 92–96% amino acid identity among most strains of ASFV. The
exceptions are; DP96R is absent from the virulent strain Malawi
LIL20/1 and a longer form of the gene (156 amino acids) is encoded
by virulent Haiti strain. DP96R has no obvious similarity with any
genes in public databases. Deletion of the DP96R gene from the
virulent strain E70 did not reduce replication within macrophagesin vitro compared to parental virus but all pigs inoculated with the
E70ΔDP96L recombinant virus survived infection and had a signiﬁ-
cant 100 to 1000-fold reduction in viraemia (Zsak et al., 1998).
The naturally attenuated OUR T88/3 isolate has been shown to
induce good levels of protection against lethal challenge with
related virulent viruses (Boinas et al., 2004; Oura et al., 2005; King
et al., 2011). However adverse reactions including fever and joint
swelling are observed in some pigs post-inoculation. In one report
(King et al., 2011) 5 out of 12 pigs immunised with OUR T88/3
developed a transient pyrexia and in another experiment one pig
(1 out of 7) inoculated with OUR T88/3 developed continued
pyrexia and was euthanised. In the current study we investigated
the effect of deleting additional genes DP71L and DP96R from the
OUR T88/3 genome to determine the effects on induction of
clinical signs and protective immunity in pigs. Although replica-
tion of this virus deletion mutant in macrophages in vitro was not
reduced, inoculation of pigs with the deletion virus, OUR T88/
3ΔDP2, reduced protection against challenge with virulent virus
OUR T88/1 compared to the parental virus OUR T88/3.Results and discussion
Isolation of recombinant virus OUR T88/3ΔDP2
The DP71L and DP96R genes were deleted from the ASFV
OURT88/3 isolate and replaced with the GUS gene under control
of the ASFV p72 promoter. This was achieved by homologous
recombination between plasmid pΔDP2loxPGUS and the virus
genome (see Materials and methods and Fig. 1). Recombinant
viruses were identiﬁed by expression of the GUS gene and puriﬁed
by infection at limiting dilution. Recombinant, virus OUR T88/
3ΔDP2, was selected for further characterisation. Genomic DNA
was isolated from wild type OUR T88/3 and OUR T88/3ΔDP2 and
analysed by PCR to test for the insertion of the GUS marker gene
and deletion of the DP71L and DP96R genes (Fig. 2). Primers
18RSEQ and 19RSEQ were designed to anneal within the MGF360
18R gene, and the non-coding region upstream of the MGF360 19R
gene, that ﬂank the insertion site. PCR using these primers
ampliﬁed a 851 bp fragment using wild type virus OUR T88/3 as
template (Fig. 2 lane 1. The size of this band is consistent with that
of a PCR product containing both the DP71L and DP96R genes and
the expected size of ﬂanking regions. A PCR using the same
primers and genomic DNA from OUR T88/3ΔDP2 ampliﬁed a
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Fig. 2. Analysis of genomic viral DNA gene deletions and insertions by PCR. Viral
DNA was extracted fromwild type OUR T88/3 virus and the recombinant virus OUR
T88/3ΔDP2. Speciﬁc fragments were ampliﬁed by PCR and the products were
analysed by electrophoresis on 1% agarose gels. The following primer sets were
used in the lanes 1+2 (18RSEQ and 19RSEQ), lanes 3+4 (18RSEQ and RGUS), lanes
5+6 (EXT18R and RGUS). The following viral genomic DNAs were used as templates
in the lanes 1, 3 and 5 (OUR T88/3) and lanes 2, 4 and 6 (OUR T88/3ΔDP2).
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Fig. 3. Replication kinetics of OUR T88/3 and recombinant OUR T88/3DDP2 viruses.
Pig bone marrow macrophages were infected at a high multiplicity of infection (m.
o.i.) of 10 or low m.o.i. of 0.1 with parental OUR T88/3 strain or recombinant virus
OUR T88/3DDP2. At various hours post-infection, as indicated on the x axis, total
virus was harvested and infectious virus titrated on 96 well plates by analysis of
infection on cultures of pig bone marrow macrophages. The virus titre (TCID50/ml)
is the mean of three individual observations. Titres obtained following infection
with viruses OUR T88/3 high m.o.i. and low m.o.i. ; OUR T88/3DDP2 high m.o.
i. and low m.o.i. are indicated.
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marker gene cassette inserted to replace the DP71L and DP96R
genes (Fig. 2 lane 2. To conﬁrm that OUR T88/3ΔDP2 contains the
GUS gene, a PCR was carried using an internal GUS gene primer,
RGUS, and primer 18RSEQ. This PCR ampliﬁed a fragment con-
sistent with the expected 1.6 kb size (Fig. 2 lane 4 when DNA from
OUR T88/3ΔDP2 was used as template. As expected no PCR
fragment was detected using these primers with wild type OUR
T88/3 DNA as template (Fig. 2 lane 3. To conﬁrm that the GUS
marker gene had been inserted at the correct site within the
genome of recombinant OUR T88/3ΔDP2, a PCR reaction was
carried out using primers RGUS and EXT18R, that anneals within
the MGF360 18R gene but is 5′ and external to the sequence of
the left ﬂanking region of pΔDP2loxPGUS. PCR with these
primers using OUR T88/3 as template generated no products
(Fig. 2 lane 5, whereas OUR T88/3ΔDP2 template generated a
2.1 kb fragment (Fig. 2 lane 6. Taken together the PCR data showed
that OUR T88/3ΔDP2 contains the GUS gene in place of the DP71L
and DP96R genes.
Growth characteristics of recombinant virus OUR T88/3ΔDP2
To investigate whether deletion of DP71L and DP96R genes
affected virus replication, the growth of OUR T88/3ΔDP2 was
compared to parental OURT88/3 virus in macrophages. Cells were
infected at high (10 TCID50/cell) or low (0.1 TCID50/cell) multiplicity of
infection and total virus was harvested from supernatants at different
times post-infection. Fig. 3 shows that there were no signiﬁcant
differences between the titres of wild OUR T88/3 and those of OUR
T88/3ΔDP2 viruses recovered at any of the time points measured, or
at either multiplicity of infection. This suggested that deletion of
DP71L and DP96R did not signiﬁcantly affect the replication of OUR
T88/3 in primary porcine macrophages.
Challenge of pigs with virulent OUR T88/1 immunized with OUR
T88/3 or OUR T88/3ΔDP2
Two groups of six pigs were immunized with either OUR T88/3
(Group 1) or OUR T88/3ΔDP2 (Group 2), three weeks later both
groups of pigs were challenged with virulent OUR T88/1. After the
initial immunisations with OUR T88/3 and OUR T88/3ΔDP2, both
groups of pigs showed similar average body temperatures and
clinical scores (data not shown). Individually, three pigs from
group 1 (pig numbers 2, 5 and 6) and three pigs from group 2(pig numbers 13, 15 and 18) showed adverse reactions in the form
of swollen joints. The clinical scores observed post-challenge of
the pigs with OUR T88/1 are shown in Fig. 4. At three days post-
challenge two pigs (numbers 14 and 18) from group 2 exhibited
clinical scores greater than 7 rising to above 15 by day four post-
challenge. At day six post-challenge these two pigs were termi-
nated for ethical reasons within the remit of the Home Ofﬁce
Licence. In group 3 (the control, unvaccinated pigs), all three
animals (numbers 19, 20 and 21) exhibited clinical scores between
1 and 2 at day three post-challenge, rising to between 8 and 9 at
day ﬁve. These pigs were all terminated at day six post-challenge.
The main difference in clinical signs observed in pigs 14 and 18 on
day 3 post-challenge, compared to the control pigs which were not
immunised with OUR T88/3 were in the more severe levels of
recumbancy and inappetance observed for pigs 14 and 18. None of
the animals in group 1 had clinical scores above 4 up to day six
post-challenge. Interestingly, pigs 14 and 18 from group 2 exhibited
higher clinical scores at days three and four post-challenge than
the non-immunized pigs from group 3. However, the clinical
scores of all pigs in group 3 continued to rise from day four to
ﬁve post-challenge, whereas those of pigs 14 and 18 decreased
from score 15 to score 8 between days four and ﬁve. All of the pigs
in group 1 and four of the pigs from group 2 had clinical scores
below 4 during the 15 days they were kept post-challenge.
Thus 66% of the pigs immunized with the deletion recombinant
OUR T88/3ΔDP2 survived subsequent challenge with virulent OUR
T88/1 whereas 100% of the animals immunised with wild type
OUR T88/3 were protected. Furthermore, there were no clear
differences in the adverse reactions observed after the initial
immunisation with the two viruses.
Virus titres obtained from blood from immunised and control pigs
before and after virulent virus challenge
EDTA blood samples were obtained from all animals in
groups 1 and 2 at days 7, 14 and 21 post-immunisation. After
challenge with virulent virus OUR T88/1, blood samples were
taken from pigs in all three groups and tissues were also taken
at post mortem. The samples were tested for the presence and
titres of ASFV genomic DNA using qPCR. The results (see Fig. 5)
show that blood from ﬁve pigs from group 1 and three pigs from
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Fig. 4. Clinical scores post-challenge with OUR T88/1. Clinical scores (y-axis) of individual pigs from the three separate groups at different days post-challenge (x-axis). Pigs
were challenged at day 0 (C-0am). Clinical scoring system as designed by King et al. (2011).
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Fig. 5. Viraemia estimated by qPCR for individual pigs post-inoculation and post-
challenge. Viraemia estimated by qPCR and expressed as ASFV genome copy per ml
of blood (y-axis) for individual pigs at different days post-inoculation and post-
challenge (x-axis). Group 1 OUR T88/3 , Group 2 OUR T88/3DDP2 and Group
3 unvaccinated . Five pigs had no detectable ASFV DNA in blood post-immunisa-
tion (pig 1—Group 1, pigs 14, 15, 17 and 18—Group 2). Four pigs had no detectable
levels of ASFV DNA in blood post-challenge (pigs 1 and 5—Group1, pigs 16 and 17—
Group 2).
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immunisation with OUR T88/3. The level of ASFV DNA detected
was less than 104 copies/ml. On days 3 and 6 post-challenge with
OUR T88/1, all three pigs from the non-immunised group 3 had
high levels of ASFV DNA which was greater than 106 copies/ml at
day 3 and rose to greater than 5107 copies/ml at day 6. The two
pigs from group 2 (numbers 14 and 18), which were not protected,
had low levels of ASFV genomic DNA in blood on day 3 (less than
6103 copies/ml) but by day 6 this had increased to greater than
5106 copies/ml. Apart from the pigs, that were terminated at day
6, only four of the six pigs from group 1 (numbers 2, 3, 4 and 6)
and two pigs from group 2 (numbers 13 and 15) had any
detectable levels of ASFV genomic DNA at day 3 post-challenge.
All of these pigs had levels of virus DNA below 104 copies per ml,
with the exception of pig 12 which had a copy number of 8104
copies per ml at day 3 post-challenge. The pigs with low copy
numbers of ASFV genomic DNA had either low or no clinical scores
and all were protected against virulent ASFV challenge. At 15 days
post-challenge one pig from group 1 (number 6) had levels of
ASFV DNA of approximately 104 copies/ml but did not show highclinical scores and was still fully protected against ASFV. Two pigs
from group 1 and two from group 2 (1, 5, 16 and 17) had no
detectable ASFV genomic DNA in the blood either post-
immunisation with OUR T88/3 or post-challenge with OUR T88/1
at the time points examined and had low or no clinical scores.
Virus titres in the spleen
The spleens of all 15 pigs were tested for the presence of ASFV
genomic DNA. DNA was detected only in the ﬁve pigs (numbers 14
and 18 from group 2 and all three pigs from group 3), which had
high clinical scores and were terminated on day 6 post-challenge.
The levels of DNA detected varied from 5103 to 3104 ASFV
genome copies per mg of tissue (data not shown).Discussion
In this study we investigated whether deletion of genes from
the ASFV low virulence isolate OUR T88/3 would reduce adverse
clinical reactions post-immunisation but maintain induction of
high levels of protection post-challenge with virulent isolate OUR
T88/1. We took advantage of the adjacent genomic location of
virulence associated genes DP71L and DP96R to delete both genes
from OUR T88/3. These genes have not previously both been
deleted from the same virus. The results showed that deletion of
DP71L and DP96R from OUR T88/3 did not reduce the replication
of the deletion mutant OUR T88/3ΔDP2 in primary porcine
macrophages in vitro compared to parental OUR T88/3. However
in vivo immunisation of pigs showed that two out of six pigs
inoculated with the deletion virus OUR T88/3ΔDP2 were not
protected against challenge with virulent virus OUR T88/1
whereas all six pigs inoculated with the parental strain OUR
T88/3 were protected.
At days 3 and 5 post-challenge the two pigs from group 2 which
were not protected (numbers 14 and 18) showed very high clinical
scores (score 8 rising to score 16) which were signiﬁcantly higher
than the clinical scores (score 2 rising to score 8) for the non-
immunised control pigs (numbers 19, 20 and 21). Although the
clinical signs of pigs 14 and 18 were enhanced at days 3 and 5
post-challenge the levels of virus replication were lower by
approximately 3log10 at day 3 and 1log10 at day 5 compared to
control unvaccinated pigs. Thus, inoculation of OUR T88/3ΔDP2 in
pigs 14 and 18 seemed to reduce virus replication post-challenge
but also reduced protection and resulted in an increase in the
clinical score at days 3 and 5 post-challenge compared to the non-
immunised pigs.
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challenge in the two pigs (14 and 18) from group 2 indicate an
immune enhancement of disease may have occurred. Immune
enhancement of disease has been documented for other virus
infections. Severe disease induced by Dengue virus (DENV) is
correlated with a second DENV infection and can be mediated by
two mutually exclusive mechanisms. One of these, antibody
enhancement of infection, occurs when cross-reactive or non-
neutralizing antibodies bind to virus particles and form complexes
which enhance virus infection of Fc receptor bearing cells, leading
to increased virus load (Halstead and O'Rourke, 1977). The second
mechanism involves cross-reactive memory T cells (Rothman and
Ennis 1999; Mongkolsapaya et al., 2003). Vaccination with RSV can
also lead to enhanced disease (Chin et al., 1969). Although RSV
titres in the lung can be reduced after RSV virus challenge disease
can be enhanced (Prince et al., 2001). A Th2-like immune response
to RSV plays a major role in the enhancement of respiratory
disease in the lungs (Graham et al., 1993). Inoculation of an
inactivated RSV vaccine in mice does elicit RSV-speciﬁc antibodies
but they have a limited afﬁnity for neutralising epitopes on the
RSV fusion protein due to a lack of afﬁnity maturation (Delgado
et al., 2009). The basis for the enhancement of clinical scores we
observed in two of the vaccinated and challenged pigs requires
further investigation. Antibody enhanced uptake of ASFV into
macrophages has not been reported previously and has not been
observed in our experiments. In one previous study treatment of
macrophages with ASFV antibody complexes did not enhance
virus replication (Alcamí and Viñuela, 1991).
In our experiment the higher clinical scores observed in pigs 14
and 18 did not correlate with increased viraemia. Thus antibody
enhanced virus uptake and replication in cells is unlikely. Instead a
possible cause for the increased clinical scores may be the
induction of an acute inﬂammatory response which initiates a
cytokine storm (Tisoncik et al., 2012).
Attempts to enhance safety and immunogenicity of vaccinia
virus (VACV) vaccine strains by targeted gene deletions have met
with some success. Deletion of either E3L, a double-stranded RNA
virus protein, B15R (soluble receptor for IL-1β) or A41 (chemokine
binding protein) from VACV were shown to increase T cell
responses with no reduction in virus replication efﬁciency (Clark
et al., 2006; Cottingham et al., 2008; Jentarra et al., 2008).
However, immunogenicity was only maintained or increased
when higher doses of inoculating virus compared to wild type
virus were administered.
Although deletion of DP71L and DP96R genes from the OUR
T88/3 strain did not reduce replication in vitro in pig macrophages,
compared to parental virus, possibly virus replication is reduced
in vivo and reduced antigen load could explain the reduced
protection induced by immunisation with OUR T88/3ΔDP2.
However from our current study it is not possible to draw this
conclusion since samples were collected at 7 day intervals post-
immunisation and transient viraemia may not have been detected.
In previous studies immunisation of pigs with virulent viruses
from which DP71L or DP96R genes were deleted did result in
reduced virus replication in pigs. No reduction in replication was
observed in macrophages in vitro but reduced viraemia (between
100 and 100 fold) and clinical signs were observed following
immunisation of pigs with E70 virus lacking DP71L gene.
In contrast deletion of DP71L from virulent Malawi LIL20/1 or
Pr4 did not reduce virulence or virus replication in vivo (Zsak et al.,
1996; Afonso et al., 1998). Similarly deletion of the DP96R gene
from the virulent virus E70 did not affect the growth character-
istics of the virus in macrophage cell cultures in vitro but levels of
viraemia in immunised pigs were reduced between 100 and 1000
fold in pigs (Zsak et al., 1996, 1998; Afonso et al., 1998). Based on
these previous studies we would expect that deletion of bothDP71L and DP96R genes could reduce virus replication in vivo. The
reduced protection we observed following immunisation with
OUR T88/3ΔDP2 compared to parental OUR T88/3 may have
resulted from a failure of the virus to prime an appropriate
protective immune response. Oura et al. (2005) demonstrated that
pigs inoculated with OUR T88/3 and depleted of CD8+ lympho-
cytes were no longer fully protected against challenge with OUR
T88/1. This indicates that CD8+ lymphocytes play an important
role in the protective immune response to ASFV infection. Deletion
of the two genes DP71L and DP96R which may encode for
protective CD8+ epitopes may be a contributing factor of towards
why the deletion virus had a reduced ability to protect against
virulent challenge. Further knowledge of the functions of DP71L
and DP96R genes are required to investigate this hypothesis.
Although deletion of DP71L and DP96R was unsuccessful at
improving OUR T88/3 as a vaccine, deletion of different ASFV
genes may give rise to an improved vaccine. An alternative vaccine
approach may be to delete ASFV genes from a parental virulent
strain of ASFV which may result in an attenuated recombinant
virus which does not give rise to adverse clinical reactions but
induces effective protection.
Immunisation with OUR T88/3ΔDP2 did not appear to signiﬁ-
cantly reduce the adverse clinical reactions observed in pigs
compared to parental OUR T88/3 since two pigs in each of groups
1 and 2 had transient joint swelling. Although it is possible that
increasing the dose of OUR T88/3ΔDP2 may improve protection
levels by increasing antigen load, this may also increase adverse
clinical reactions.
Therefore future research will focus on understanding the
mechanisms involved in induction of the clinical reactions and
testing different combinations of gene deletions from the ASFV
genome to improve the safety and efﬁcacy of attenuated viruses.Materials and methods
Cells and viruses
Non-virulent, non-haemabsorbing ASFV isolate OUR T88/3 and
virulent haemabsorbing isolate OUR T88/1 were both obtained
from Ourique in Portugal and have been described previously
(Boinas et al., 2004). Both OUR T88/3 and OUR T88/1 are p72
genotype I (Bastos et al., 2003; Chapman et al., 2008). Viruses were
grown in primary macrophage cultures derived from bone marrow
(Malmquist and Hay,1960). Titres of virus were determined as the
amount of virus causing haemadsorption (for HAD isolates) or
cytopathic effects (for non-HAD isolates) in 50% of infected
cultures (HAD50/ml or TCID50/ml).
Construction of plasmid transfer vector pΔDP2loxPGUS
The plasmid transfer vector pΔDP2loxPGUS was constructed to
facilitate the deletion of genes DP71L and DP96R from the genome of
virus OUR T88/3. Using OUR T88/3 genomic DNA as template, a
445 bp fragment (Flank L) located at the 3′ terminus of the MGF360
18R gene at position 169125–169570 immediately upstream of the
DP71L gene was ampliﬁed using the PCR primers DP71L 5(GTTTA-
AACTTAAGCTTTTGCGCGGCCTTGAGGTCAAG) and DP71L 3(CGCGGAT-
CCATCGGTACCCGCTCGTGGGGTGAAAGAACGTCC). A 440 bp fragment
(Flank R) located in the non-coding region upstream of the MGF 360
19R gene at position 170195–170635 and downstream of the DP96R
gene to be deleted was ampliﬁed using the PCR primers DP96R
5(GGATCCAGCGGCCGCACGTACGTGTAAGTTTATAAACTATATAG) and
DP96R 3(CCCTTCTAGACTCGAGAGATAACCATGGAAATTTTGTA). Flank
L fragment was digested with Hind III and Kpn I and ligated into the
vector pMGFloxPGUS vector (Abrams and Dixon, 2012) which was
C.C. Abrams et al. / Virology 443 (2013) 99–105104also digested with Hind III and Kpn I to create plasmid pFlankL-GUS.
The pFlankL-GUS vector included the GUS gene under the control of
the p72 promoter ﬂanked by loxP sites. The ﬂankR fragment was
digested with Not I and Xho I and ligated into the vector pFlankL-GUS
digested with the same enzymes to create the transfer vector
pΔDP2loxPGUS. The plasmid pΔDP2loxPGUS contains a GUS marker
gene ﬂanked on the left hand side by the 3′ terminal section of the
MGF360 18R gene which lies immediately upstream of the DP71L
gene. To the right hand side of the GUS gene was located a fragment
(440 bp) of the non-coding region upstream of the MGF360 19R gene
which lies immediately downstream of the DP96R gene (Fig. 1).Construction and isolation of recombinant virus OUR T88/3ΔDP2
Primary pig bone marrow macrophages (35 mm dish, 106 cells)
were infected with OUR T88/3 at a multiplicity of infection (m.o.i). of
10 and incubated at 37 1C for 5 h, and thenwashed with Earle's saline
(10% porcine serum, penicillin/streptomycin 10,000 mmg/ml).
A transfection mixture containing 250 ml Optimem (Gibco-Life Tech-
nologies), 5 mg pΔDP2loxPGUS and 7.5 ml TRANS-IT LT-1 (Mirus)
transfection reagent was incubated at 20 1C for 20 min before adding
it to the infected cells. Incubation was continued at 37 1C for 4 h
before the addition of 1 ml Earle's saline and continued incubation at
37 1C. Virus was harvested from the infected and transfected cells
72 h post-infection and cell debris removed by centrifugation.
Aliquots of virus containing supernatant were used to infect bone
marrowmacrophages on 96 well plates. At 90 h post-infection Earle's
saline containing 100 mg/ml 5-bromo-4-chloro-1H-indol-3-yl β-D-
glucopyranosiduronic acid (X-Gluc) was added and wells appearing
‘blue’ containing recombinant GUS expressing viruses were
harvested. Infections at limiting dilution were further carried out
on bone marrow macrophages containing X-Gluc until only one blue
well per 96 well plate was observed to indicate infection with the
recombinant deletion virus. No evidence of virus infection (cyto-
pathic effect (cpe)) was observed in the other 95 wells. High titre
stocks of recombinant virus OUR T88/3ΔDP2 were grown up on pig
bone marrow macrophages.Puriﬁcation and analysis of viral genomic DNA
Viral genomic DNA from OUR T88/3 or OUR T88/3ΔDP2 virus
harvests was puriﬁed from 300 ml of supernatant from infected cells
using a GE Healthcare Illustra genomic Prep Mini Spin kit. Analysis
of viral genomic DNA was carried out by PCR using the speciﬁc DNA
primers 18RSEQ (GGGACTAGTCTCCGCCCCACTGCG), 19RSEQ (GTT-
TAGTGTGGTAGCAACACTATC, RGUS (CCTTCTCTGCCGTTTCCAAAT-
CGCCGC) and EXT18R (CGCTCAGATGGGCAATCTGAGG).Pig immunisation and challenge
Pigs used were cross-bred, large white Landrace, of average
weight 15 kg at the ﬁrst inoculation. All pigs were maintained in
high security SAPO4 facilities throughout and the experiment
performed under Home Ofﬁce licence PPL 70–6369. One group
of six pigs were inoculated intramuscularly with 104TCID50 of low
virulence isolate OUR T88/3 (Group 1) or deletion recombinant
OUR T88/3ΔDP2 (Group 2). Three weeks later both groups 1 and
2 and a third group (Group 3) containing three non-immunised
pigs, were challenged intramuscularly with 104 HAD of virulent
ASFV isolate OUR T88/1. ASFV-inoculated and challenged pigs
were monitored for body temperature and other clinical signs
and these were scored as reported by King et al. (2011). All pigs
were examined by post-mortem at termination and spleen and
lymph tissues were collected.Quantitative PCR analysis of virus copy number in blood and tissues
DNA was extracted from whole peripheral blood at different
days post-inoculation and post-challenge or from tissues at post-
mortem and analysed by quantitative PCR (qPCR) as described
previously (King et al., 2003).Acknowledgment
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